TG Therapeutics Inc

NASDAQ:TGTX  
5.92
-0.07 (-1.17%)
Regulatory, Earnings Announcements

TG Therapeutics Announces Results From The Ultimate I & II Phase 3 Trials Of Investigational Ublituximab

Published: 08/25/2022 11:48 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Announces Results From the Ultimate I & Ii Phase 3 Trials of Investigational Ublituximab in Rms Published in the New England Journal of Medicine.
Tg Therapeutics Inc- Ultimate I and Ii Demonstrated Significant Reductions in Risk of Relapses, As Well As Reduction of Active Or New Brain Lesions.
Tg Therapeutics Inc- Marketing Applications for Ublituximab to Treat Patients With Rms Have Been Accepted, Are Currently Under Review by US FDA and Ema.
Revenue is expected to be $1.46 Million
Adjusted EPS is expected to be -$0.36

Next Quarter Revenue Guidance is expected to be $8.26 Million
Next Quarter EPS Guidance is expected to be -$0.34

More details on our Analysts Page.